Media stories about China Biologic Products (NASDAQ:CBPO) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. China Biologic Products earned a news impact score of 0.08 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.7768600637257 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media headlines that may have effected Accern Sentiment’s scoring:

CBPO has been the subject of a number of research analyst reports. Zacks Investment Research upgraded China Biologic Products from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th. BidaskClub cut China Biologic Products from a “hold” rating to a “sell” rating in a report on Sunday, July 16th. Finally, Jefferies Group LLC reiterated a “buy” rating on shares of China Biologic Products in a report on Friday, August 4th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the stock. China Biologic Products currently has a consensus rating of “Hold” and a consensus target price of $137.50.

China Biologic Products (CBPO) traded down 0.74% during trading on Friday, hitting $80.40. The stock had a trading volume of 233,835 shares. China Biologic Products has a one year low of $76.26 and a one year high of $125.99. The firm has a market cap of $2.22 billion, a price-to-earnings ratio of 20.94 and a beta of 1.75. The stock’s 50-day moving average is $89.59 and its 200 day moving average is $101.61.

China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the Zacks’ consensus estimate of $1.30 by $0.05. The business had revenue of $89.28 million during the quarter, compared to the consensus estimate of $97.33 million. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. The business’s revenue for the quarter was down 2.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.26 earnings per share. Equities analysts anticipate that China Biologic Products will post $4.93 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “China Biologic Products (CBPO) Receiving Somewhat Positive Media Coverage, Analysis Shows” was posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at

China Biologic Products Company Profile

Insider Buying and Selling by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with's FREE daily email newsletter.